Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIA study of endocrine therapy sequencing with ribociclib in HR-positive/HER2-negative advanced breast cancer
NL-OMON59535Phase 3Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribociclib, fulvestrant, letrozole and anastrozole in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free survival after two lines of treatment. Started Nov 2017; status: active, not recruiting.
02
Drugs
ribociclibfulvestrantletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59535.